

Claims

1. A composition comprising an agonistic anti-4-1BB antibody, or fragment thereof which stimulates the 4-1BB receptor.
- 5 2. A composition according to claim 1, wherein the composition further comprises an agonistic anti-CD40 antibody, or fragment thereof which stimulates the CD40 receptor.
- 10 3. A composition according to claims 1 or 2, wherein the composition further comprises one or more molecules selected from proteins, polypeptides, peptides, viruses, or nucleic acid sequences having or encoding a class I MHC or class II MHC-restricted T cell epitope.
- 15 4. A composition according to any one of claims 1 - 3, wherein the anti-4-1BB antibody, or the fragment thereof, is human, humanised, chimeric or Deimmunised™.
- 20 5. A composition according to any one of claims 2 - 4, wherein the anti-CD40 antibody, or fragment thereof is human, humanised, chimeric or Deimmunised™.
- 25 6. A use of an agonistic anti-4-1BB antibody, or fragment thereof which stimulates the 4-1BB receptor in the manufacture of a medicament for the induction of systemic T cell immunity against an antigen.
- 30 7. A use of an agonistic anti-CD40 antibody, or fragment thereof which stimulates the CD40 receptor in the manufacture of a medicament for the induction of systemic T cell immunity against an antigen.
8. A use according to claim 6, wherein the anti-4-1BB antibody, or the fragment thereof is combined with the anti-CD40 antibody, or the fragment thereof in the manufacture of a medicament for the induction of systemic T cell immunity against a class I MHC or class II MHC-restricted T cell epitope.

8. A use according to claims 6 or 8, wherein the anti-4-1BB antibody, or the fragment thereof, and/or the anti-CD40 antibody, or the fragment thereof, is combined with one or more molecules selected from proteins, polypeptides, peptides, viruses, or nucleic acid sequences having or encoding a class I MHC or class II MHC-restricted T cell epitope in the manufacture of a medicament for the induction of systemic T cell immunity against an antigen.
9. A use according to any one of claims 6 - 8, wherein the antigen is an antigen of a tumor or tumor cells.
10. A use according to any one of claims 6 - 8, wherein the antigen is an antigen of an infectious agent.
11. A use according to claims 9 or 10, wherein the antigen is an HPV antigen.
12. A use according to claims 11, wherein the antigen is a peptide having the sequence RAHYNIVTF (SEQ ID NO:3).